BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 34115902)

  • 1. Tumor cell-intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mTOR-mitochondrial ROS signaling.
    Martins C; Rasbach E; Heppt MV; Singh P; Kulcsar Z; Holzgruber J; Chakraborty A; Mucciarone K; Kleffel S; Brandenburg A; Hoetzenecker W; Rahbari NN; DeCaprio JA; Thakuria M; Murphy GF; Ramsey MR; Posch C; Barthel SR; Schatton T
    Sci Adv; 2024 Jan; 10(3):eadi2012. PubMed ID: 38241371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMiDs uniquely synergize with TKIs to upregulate apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells expressing a dominant-negative IKZF1 isoform.
    Harama D; Yahata T; Kagami K; Abe M; Ando N; Kasai S; Tamai M; Akahane K; Inukai T; Kiyokawa N; Ibrahim AA; Ando K; Sugita K
    Cell Death Discov; 2021 Jun; 7(1):139. PubMed ID: 34117218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers.
    Shan KS; Bonano-Rios A; Theik NWY; Hussein A; Blaya M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased expression of
    Liu W; Xiao Z; Dong M; Li X; Huang Z
    Oncol Lett; 2024 Mar; 27(3):97. PubMed ID: 38288038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Logic-based modeling and drug repurposing for the prediction of novel therapeutic targets and combination regimens against E2F1-driven melanoma progression.
    Singh N; Khan FM; Bala L; Vera J; Wolkenhauer O; Pützer B; Logotheti S; Gupta SK
    BMC Chem; 2023 Nov; 17(1):161. PubMed ID: 37993971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of GP-2250 on cultured virus-negative Merkel cell carcinoma cells: preliminary results.
    Gambichler T; Majchrzak-Stiller B; Peters I; Becker JC; Strotmann J; Abu Rached N; Müller T; Uhl W; Buchholz M; Braumann C
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10831-10840. PubMed ID: 37311987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Merkel cell carcinoma.
    Wallis S; Durham-Hall A; Tandon N; Brotherston TM; Shrestha BM
    JNMA J Nepal Med Assoc; 2010; 49(178):151-4. PubMed ID: 21485603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy.
    Chamcheu JC; Roy T; Uddin MB; Banang-Mbeumi S; Chamcheu RN; Walker AL; Liu YY; Huang S
    Cells; 2019 Jul; 8(8):. PubMed ID: 31370278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts.
    Fang B; Kannan A; Zhao S; Nguyen QH; Ejadi S; Yamamoto M; Camilo Barreto J; Zhao H; Gao L
    Sci Rep; 2020 Jun; 10(1):8867. PubMed ID: 32483262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
    Yamaji M; Ota A; Wahiduzzaman M; Karnan S; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Haniuda M
    Cancer Med; 2017 Nov; 6(11):2646-2659. PubMed ID: 28960945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Akt/mTOR/4E-BP1 pathway signal activation and mutations of PIK3CA in Merkel cell polyomavirus-positive and Merkel cell polyomavirus-negative carcinomas.
    Iwasaki T; Matsushita M; Nonaka D; Kuwamoto S; Kato M; Murakami I; Nagata K; Nakajima H; Sano S; Hayashi K
    Hum Pathol; 2015 Feb; 46(2):210-6. PubMed ID: 25466966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth.
    Kannan A; Lin Z; Shao Q; Zhao S; Fang B; Moreno MA; Vural E; Stack BC; Suen JY; Kannan K; Gao L
    Oncotarget; 2016 Feb; 7(6):6576-92. PubMed ID: 26536665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic mTOR activation promotes cell survival in Merkel cell carcinoma.
    Lin Z; McDermott A; Shao L; Kannan A; Morgan M; Stack BC; Moreno M; Davis DA; Cornelius LA; Gao L
    Cancer Lett; 2014 Mar; 344(2):272-281. PubMed ID: 24262658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel AKT inhibitor afuresertib suppresses human Merkel cell carcinoma MKL-1 cell growth.
    Wu JH; Limmer AL; Narayanan D; Doan HQ; Simonette RA; Rady PL; Tyring SK
    Clin Exp Dermatol; 2021 Dec; 46(8):1551-1554. PubMed ID: 34115902
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.